Current Environment:

To deliver on the promise of stem cell research as swiftly as possible, the Stem Cell Program at Boston Children’s Hospital devised a meticulous business plan. Developed in consultation with business, philanthropic and biotech leaders, the plan lays out the milestones and investments necessary to bring the Program’s first stem cell therapy to clinical trials within five years and deliver renewed hope to patients.

Affiliate members

The Stem Cell Community at Boston Children’s Hospital is a broad and active one. More than 70 faculty members from a wide range of disciplines and departments at Boston Children’s Hospital have joined the Stem Cell Program at Boston Children’s Hospital as Affiliate Members. Although not working directly within the Program, many Affiliate Members are conducting research or exploring investigatory avenues closely related to its work. The Affiliates participate in a range of semi-annual events sponsored by the Stem Cell Program; through these events, members have an opportunity to exchange information, share discoveries, and build collaborations. The expertise, insights and research of the Affiliate Members add significantly to the resources of the Program, and their individual research initiatives are creating new pathways toward finding treatments for disease.

Affiliate labs

Alt Lab

Benowitz Lab

Bischoff Lab

Breault Lab

Bodamer Lab

Burns Lab

Buttermore Lab

Craft Lab

Fauza Lab

Geha Lab

General Renal Program

Gussoni Lab

He Lab

Hematopoietic (Stem) Cell Transplant Program

Hildebrandt Lab

Human Neuron Core

Ingber Lab

Kean Lab

Koehler Lab

Kreidberg Lab

Kunkel Lab

Lehtinen Lab

Lencer Lab

Lieberman Lab

Luo Lab

Neurobiology Program

Newborn Medicine Research

Ordova-Montanes Lab

Orkin Lab

Perlmutter Lab

Pu Lab

Rosenberg Lab

Rossi Lab

Sahin Lab

Sankaran Lab

Silberstein Lab

Smith Lab

Umemori Lab

Urology Research

Vascular Biology Program

Walsh Lab

Williams Lab

Woolf Lab

Yuan Lab

Zetter Lab

 

 

 

Stem cell program business plan

Leonard Zon, MD, and George Q. Daley, MD, PhD, launched the Stem Cell Program at Boston Children’s Hospital in 2004. These two physician-scientists had served on multiple corporate and nonprofit boards, and had experience as founding members of biotech start-ups.

They recognized the value of applying sound business principles and strategies to the new research program. In a startup, the process of planning is very efficient and every detail is taken into consideration, and they wanted to echo that process with the new program. Drs. Zon and Daley presented this concept to the Stem Cell Task Force, an advisory group made up of business, philanthropic, and biotech leaders with whom they meet regularly.

The plan lays out the milestones and investments necessary to bring the program’s first stem cell therapy to clinical trials within five years and deliver renewed hope to patients.  Because research and especially stem cell science is an incredibly fluid and growing area of research, the business plan is designed to be flexible enough to accommodate changes in science, technology, and research options without compromising the goal. Once a year, the plan is reviewed in detail with the Stem Cell Task Force, progress is assessed, and essential changes to the plan are made based on changes in science.

hESC Research Review Process

Proposals are reviewed to insure that scientific, institutional, and legal standards will be appropriately met in the course of the research. The hospital’s Committee on Clinical Research (IRB) and the Office of Research Administration conduct a rigorous and detailed review of each hESC research proposal. These groups and others at the hospital provide ongoing counsel to researchers and physicians around all aspects of stem cell research.

As recommended by the National Academy of Sciences, all applications to conduct hESC research at Boston Children’s Hospital are also reviewed by an Embryonic Stem Cell Research Oversight Committee (ESCRO), which includes public representatives as well as persons with expertise in developmental biology, stem cell research, molecular biology, assisted reproduction, and ethical and legal issues in human embryonic stem cell research.

No hESC work can be undertaken at Boston Children’s without project specific authorization from the ESCRO, the institutional IRB, and the Office of Research Administration.

Additional Resources